PXRB (PixarBio) Preferred Dividends : $0.00 Mil (TTM As of Sep. 2016)

View and export this data going back to 2016. Start your Free Trial

What is PixarBio Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. PixarBio's preferred dividends for the three months ended in Sep. 2016 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Sep. 2016 was $0.00 Mil.

PixarBio Preferred Dividends Historical Data

The historical data trend for PixarBio's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Preferred Dividends Chart

PixarBio Annual Data

Trend

Dec14

Dec15

Preferred Dividends

PixarBio Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Preferred Dividends	Get a 7-Day Free Trial					-	-	-	-	-

PixarBio Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

PixarBio (GREY:PXRB) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

PixarBio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155

Website

https://www.pixarbio.com

PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.